NICE rejects Yondelis (trabectedin) as a treatment for ovarian cancer- Pharma Mar

The National Institute for Health and Care Excellence (NICE) again did not recommend Yondelis (trabectedin) from Pharma Mar plus pegylated liposomal doxorubicin (PLDH) in its preliminary guidance as a treatment for ovarian cancer in patients sensitive to platinum or platinum based therapies, as no advantage was shown over the current standard of care, being paclitaxel and platinum based therapy.

Sir Andrew Dillon, CEO of NICE, stated "The evidence did, however, show that trabectedin is associated with high rates of toxicity on the body’s blood system compared with other, currently available drugs. It was these factors and not necessarily the cost of the treatment that concerned the committee most.”